Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.

Andrisani G, Armuzzi A, Papa A, Marzo M, Felice C, Pugliese D, De Vitis I, Rapaccini GL, Guidi L.

J Gastrointestin Liver Dis. 2013 Mar;22(1):21-5.

2.

Can ELISpot replace the tuberculin skin test for latent tuberculosis?

Greveson K.

Br J Nurs. 2009 Nov 12-25;18(20):1248-54. Review.

PMID:
20081663
3.
4.

Screening of tuberculosis before biologics.

Mrozek N, Pereira B, Soubrier M, Gourdon F, Laurichesse H.

Med Mal Infect. 2012 Jan;42(1):1-4. doi: 10.1016/j.medmal.2011.08.002. Epub 2011 Sep 9. Review.

PMID:
21907513
5.

Biologic Agents and Tuberculosis.

Dobler CC.

Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0026-2016. Review.

PMID:
28084208
6.

Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis.

Wong SH, Gao Q, Tsoi KK, Wu WK, Tam LS, Lee N, Chan FK, Wu JC, Sung JJ, Ng SC.

Thorax. 2016 Jan;71(1):64-72. doi: 10.1136/thoraxjnl-2015-207811. Epub 2015 Dec 11. Review.

PMID:
26659461
7.

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.

Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C.

Eur Respir J. 2010 Nov;36(5):1185-206. doi: 10.1183/09031936.00028510. Epub 2010 Jun 7.

8.

Tuberculosis and Crohn's Disease Revisited.

Onal IK, Kekilli M, Tanoglu A, Erdal H, Ibis M, Arhan M.

J Coll Physicians Surg Pak. 2015 Jun;25(6):443-8. doi: 06.2015/JCPSP.443448. Review.

PMID:
26100999
9.

[Natural history, complications, safety and pregnancy in inflammatory bowel disease].

Chaparro M.

Gastroenterol Hepatol. 2015 Sep;38 Suppl 1:20-31. doi: 10.1016/S0210-5705(15)30016-9. Review. Spanish.

PMID:
26520193
10.

[Side effects and contraindications for biological therapy in inflammatory bowel disease].

Troskot B, Simunić M.

Acta Med Croatica. 2013 Apr;67(2):131-43. Review. Croatian.

PMID:
24471296
11.

[Screening for opportunistic infections and vaccination before introduction of biologic therapy].

Sincić BM, Vince A.

Acta Med Croatica. 2013 Apr;67(2):165-70. Review. Croatian.

PMID:
24471299
12.

Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?

McLean MH, Neurath MF, Durum SK.

Inflamm Bowel Dis. 2014 Feb;20(2):389-97. doi: 10.1097/01.MIB.0000437616.37000.41. Review.

PMID:
24356385
13.

Screening for latent tuberculosis and gastrointestinal parasite infections in Gurkha recruits: research driving policy change.

O'Shea MK, Fletcher TE, Tupper D, Ross D, Wilson D.

J R Army Med Corps. 2014 Jun;160(2):180-2. doi: 10.1136/jramc-2014-000259. Epub 2014 Mar 7. Review.

PMID:
24607484
14.

Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.

Goyal A, Goyal K, Merola JF.

Am J Clin Dermatol. 2015 Jun;16(3):179-95. doi: 10.1007/s40257-015-0124-x. Review.

PMID:
25854805

Supplemental Content

Support Center